Catalyst Pharmaceuticals (CPRX) Expected to Announce Earnings on Wednesday

Catalyst Pharmaceuticals (NASDAQ:CPRX) is expected to post its quarterly earnings results after the market closes on Wednesday, February 26th. Analysts expect Catalyst Pharmaceuticals to post earnings of $0.32 per share and revenue of $134.20 million for the quarter. Parties that wish to register for the company’s conference call can do so using this link.

Catalyst Pharmaceuticals Price Performance

Shares of NASDAQ CPRX opened at $21.63 on Monday. Catalyst Pharmaceuticals has a 1 year low of $13.49 and a 1 year high of $24.64. The firm has a market cap of $2.58 billion, a PE ratio of 18.33, a price-to-earnings-growth ratio of 3.31 and a beta of 0.80. The company has a 50 day simple moving average of $22.25 and a 200 day simple moving average of $21.37.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on CPRX. Bank of America reiterated a “buy” rating and set a $30.00 price target on shares of Catalyst Pharmaceuticals in a report on Thursday, January 9th. Stephens initiated coverage on Catalyst Pharmaceuticals in a research note on Monday, November 18th. They issued an “overweight” rating and a $35.00 price target for the company. HC Wainwright lifted their target price on shares of Catalyst Pharmaceuticals from $30.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday, January 10th. Truist Financial boosted their price target on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, November 11th. Finally, Baird R W raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Monday, February 3rd. Nine analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Catalyst Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $32.25.

Insider Transactions at Catalyst Pharmaceuticals

In other news, Director Molly Harper sold 17,500 shares of Catalyst Pharmaceuticals stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $22.00, for a total transaction of $385,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Steve Miller sold 50,000 shares of the business’s stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $21.93, for a total transaction of $1,096,500.00. Following the sale, the insider now directly owns 686,996 shares of the company’s stock, valued at approximately $15,065,822.28. The trade was a 6.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 79,500 shares of company stock valued at $1,754,140 over the last ninety days. 11.00% of the stock is owned by company insiders.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.